07.01.2014 Carl Zeiss Meditec AG  DE0005313704

DGAP-Adhoc: Carl Zeiss Meditec strengthens Portfolio of Intraocular Lenses with the Acquisition of Aaren Scientific


 
Carl Zeiss Meditec AG / Key word(s): Acquisition 07.01.2014 12:47 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------------


Carl Zeiss Meditec strengthens Portfolio of Intraocular Lenses with the
Acquisition of Aaren Scientific

Jena, 7 January 2014: Carl Zeiss Meditec AG (ISIN: DE0005313704) today
announces the acquisition of the U.S.-based manufacturer of intraocular
lenses (IOLs) Aaren Scientific Inc. (Aaren) headquartered in Ontario,
California. The share purchase agreement to acquire 100% of shares in Aaren
should be signed today. The transaction is expected to close immediately.
Aaren will be incorporated into the strategic business unit Surgical
Ophthalmology of Carl Zeiss Meditec AG, complementing existing IOL sites in
Berlin, Germany and La Rochelle, France.

Aaren has more than two decades worth of experience in manufacturing IOLs
and owns rights in CE and FDA approved material for the manufacturing of
IOLs. Furthermore, the company has a broad range of highly competitive
products. In 2012, Aaren achieved total revenues of approximately USD 20 m,
mainly generated outside of the U.S. Aaren currently has 235 employees. The
majority of shares in the company had previously been owned by private
investment firm James E Sowell Company Inc. of Dallas, Texas, as well as
other investors, including the CEO and co-founder of Aaren Scientific, Rick
Aguilera, who will stay on board with his management team.

The purchase price for 100% of the shares of Aaren Scientific amounts to
USD 70 m in cash on a cash free/debt free basis.

Insertion of an intraocular lens after cataract surgery is the most
commonly performed ophthalmic surgical procedure. While the vast majority
of IOLs implanted to treat cataracts are monofocal lenses, Carl Zeiss
Meditec has especially shaped the market with its multifocal intraocular
lenses. Carl Zeiss Meditec offers cataract surgeons a complete integrated
solution to treat cataracts from diagnosis to surgery and aftercare. About
70% of all cataract patients come in contact with a product of Carl Zeiss
Meditec. The Strategic Business Unit Surgical Ophthalmology has reported
very encouraging growth rates driven by strong demand for innovative IOLs
over the last few years.


Contact for investors Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG Tel. +49 3641 220-116, E-Mail: [email protected] Press contact Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG Tel. +49 3641 220-331, E-Mail: [email protected] 07.01.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Carl Zeiss Meditec AG Göschwitzer Str. 51-52 07745 Jena Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: [email protected],[email protected] Internet: www.meditec.zeiss.de ISIN: DE0005313704 WKN: 531370 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.189,90 1.280,86 1.459,32 1.335,45 1.646,79 1.902,84 2.089,30
EBITDA1,2 205,07 228,41 313,03 237,98 435,20 466,65 422,19
EBITDA-Marge3 17,23 17,83 21,45 17,82 26,43 24,52
EBIT1,4 180,83 197,13 264,66 177,55 373,61 396,88 348,12
EBIT-Marge5 15,20 15,39 18,14 13,30 22,69 20,86 16,66
Jahresüberschuss1 135,78 126,23 160,58 123,42 237,52 295,91 292,01
Netto-Marge6 11,41 9,86 11,00 9,24 14,42 15,55 13,98
Cashflow1,7 37,73 187,21 219,63 178,53 362,66 188,20 250,86
Ergebnis je Aktie8 1,57 1,41 1,79 1,37 2,64 3,29 3,25
Dividende8 0,55 0,55 0,65 0,50 0,90 1,10 0,42
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Carl Zeiss Meditec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
531370 115,800 Halten 10.357,22
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
32,62 35,86 0,93 56,77
KBV KCV KUV EV/EBITDA
5,03 41,29 4,96 22,47
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,10 1,10 0,95 21.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
09.02.2024 08.05.2024 06.08.2024 12.12.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,90% 20,83% 17,16% -6,04%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Carl Zeiss Meditec AG  ISIN: DE0005313704 können Sie bei EQS abrufen


Medtech , 531370 , AFX , XETR:AFX